Page URL:

Aspirin cuts hereditary bowel cancer risk by 60 percent

31 October 2011
Appeared in BioNews 631

Taking a daily aspirin has been recommended for people with a high risk of an inherited form of bowel cancer. Results published in the Lancet suggested the risk for those with Lynch syndrome could be cut by 63 percent.

Professor Sir John Burn, of Newcastle University, who led the study, told the BBC that the evidence 'seems overwhelmingly strong'.

A daily low dose of aspirin is prescribed to people at risk of heart attack or stroke, and some researchers had noticed that these groups showed lower rates of colorectal cancer. The Colorectal Adenoma/carcinoma Prevention Programme (CAPP2) study – the first double-blind, randomised controlled trial of aspirin focusing on the prevention of cancer – confirmed it could have a dramatic effect on the development of colorectal tumours.

'People who've got a clear family history of, particularly, bowel cancer should seriously consider adding low dose aspirin to their routine and particularly those people who've got a genetic predisposition', Professor Burn recommended.

Lynch syndrome, or hereditary nonpolyposis colorectal cancer (HNPCC), is an inherited form of colorectal cancer caused by genetic mutations, which around one in 1,000 people carry. Around 90 percent of men and 70 percent of women with HNPCC will develop bowel cancer by the age of 70. They are also at risk of other cancers, such as cancer of the uterus, ovary, breast, prostate, brain, pancreas, gall bladder, ureter, stomach and kidney.

Participants in the CAPP2 trial took 600 mg of either aspirin or placebo daily between 1999 and 2005. The 861 patients were followed for up to ten years at 43 centres across 16 countries.

Data in 2007 showed no difference between the two groups, but an assessment in 2010 showed that while 34 people had developed new colorectal cancers in the placebo group, there were only 19 new cancers in the aspirin-treated group. Furthermore, it found that there was an overall reduction in other cancers – 23 in the placebo group, and only 10 in the aspirin group.

Based on these results, giving aspirin to people at risk could prevent up to 10,000 cancers over the next decade, which could save up to 1,000 lives. As people in the study taking aspirin showed no more adverse effects than those taking placebo, this could be a safe and cost-effective way of preventing cancer.

Taking aspirin is not risk-free, as it can increase the risk of ulcers and bleeding in the gut in some people, but, as Professor Burn commented: 'If we can prevent 10,000 cancers in return for 1,000 ulcers and 100 strokes, in most people's minds that's a good deal'.

It is unclear quite how aspirin works – it may be through its role as a COX2 inhibitor, it could act to kill of cells in the early stages of the cancers or even by destroying the stem cells that are likely to differentiate into cancer cells.

Further work will come in the form of CAPP3, a trial to optimise the dose and duration of the treatment with aspirin.

Aspirin cuts cancer risk in people with an inherited susceptibility
Guardian |  28 October 2011
Aspirin cuts hereditary cancer risk
Press Association |  28 October 2011
Aspirin 'should be recommended' to cut bowel cancer risk in people with inherited syndrome
Cancer Research UK |  28 October 2011
Daily aspirin 'blocks bowel cancer'
BBC |  28 October 2011
Daily aspirin cuts risk of colorectal cancer
New Scientist |  28 October 2011
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial
The Lancet |  28 October 2011
7 December 2015 - by Richard Kennedy 
The 'wonder drug' aspirin has proven benefits in cardiac disease and stroke, and it is increasingly thought to have a role in cancer prevention, but its wider use in support of infertility and assisted reproduction is controversial...
26 October 2015 - by Dr Jane Currie 
Low-dose aspirin may increase the chances of pregnancy in certain women, according to a US study...
23 March 2015 - by Rhys Baker 
Whether or not aspirin reduces a person's risk of bowel cancer could all be down to their genetic make-up, according to a US study...
7 January 2013 - by Chris Baldacci 
Two rare genetic mutations have been linked to a higher risk of developing bowel cancer...
29 October 2012 - by Purvi Shah 
Regular use of aspirin may extend the lives of colon cancer patients whose tumour carries a specific gene mutation, scientists report...
15 August 2011 - by Victoria Kay 
There is insufficient evidence to suggest that taking aspirin during IVF increases a woman's chances of conceiving, according to the latest Cochrane Systematic Review...
22 November 2010 - by Sarah Pritchard 
UK researchers have identified a type of genetic variation which allows bowel cancer patients to live on average three months longer than those without the variant....
30 November 2009 - by Sarah Pritchard 
The GSTP gene, which helps to protect the human body from harmful chemicals such as tobacco smoke, may also play a role in protection against the development of bowel cancer, say UK researchers....
28 September 2009 - by Dr Will Fletcher 
Scientists in the UK have found that a daily dose of aspirin may halve the chance of men with Lynch Syndrome developing colon cancer, one of the three most common cancers in developed countries. Lynch Syndrome is an inherited condition, which increases vulnerability to cancers of the colon, rectum, stomach, brain, liver, womb and elsewhere. Whilst the syndrome only accounts for five per cent of all colon cancer cases, the new findings are significant because men with the condition normally ha...
30 June 2006 - by Dr Jess Buxton 
UK scientists have developed a new genetic test to identify bowel cancer patients who have an inherited form of the disease. The team, based at Edinburgh University, says that the test could also be used to detect people at high risk of developing the disease, before...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.